Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections

Bibliography

• GROLL AH, PISCITELLI SC, WALSH TJ: Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv. Pharmacal (1998) 44:343–500.
   PubMedGoogle Scholar
• BOUFFARD FA, ZAMBIAS RA, DROPINSKI JF et al.: Synthesis and antifungal activity of water-soluble pneumocandin Bo derivatives: L-705,589, L-731, 373, and L-733560. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (1993):350.
   Google Scholar
• BOUFFARD FA, DROPINSKI JF, BALKOVEC JM et al.: L-743,872, a novel antifungal lipopeptide: synthesis and structure-activity relationships of new aza-substituted pneumocandins. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (1996):F–27.
   Google Scholar
• •Original report on the synthesis of caspofungin.
   Google Scholar
• KURTZ MB, DOUGLAS CM: Lipopeptide inhibitors of fungal glucan synthase. I Med. Vet. Myra (1997) 35:79–86.
   PubMedGoogle Scholar
• •A comprehensive review of the echinocandin lipopeptides.
   Google Scholar
• THOMPSON JR, DOUGLAS CM, LI W et al.: A glucan synthase FKS1 homolog in Cryptocaccus neaformaris is single copy and encodes an essential function. j. Bacterial (1999) 181:444–453.
   PubMed Web of Science ®Google Scholar
• DEBONO M, GORDEE RS: Antibiotics that inhibit fungal cell wall development. Ann. Rev Microbial (1994) 48:471–497.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of cell-wall active antifungal compounds.
   Google Scholar
• GEORGOPAPADAKOU NH: Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors. Expert Opin. Investig. Drugs (2001) 10:269–280.
   Google Scholar
• •A comprehensive review of the echinocandin lipopeptides.
   Google Scholar
• HECTOR RF: Compounds active against cell walls of medically important fungi. Clin. Microbial. Rev (1993) 6:1–21.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of cell-wall active antifungal compounds.
   Google Scholar
• FELDMESSER M, KRESS Y, MEDNICK A, CASADEVALL A: The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptocaccus neaformans. J Infect. Dis. (2000) 182:1791–1795.
   PubMed Web of Science ®Google Scholar
• FOTHERGILL AW, SUTTON DA, RINALDI MG: Antifungal susceptibility testing of Merck L-743,872 against a broad range of fungi. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (1996):F–29.
   Google Scholar
• BARTIZAL K, GILL CJ, ABRUZZO GK et al.: In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. (1997) 41:2326–2332.
   PubMed Web of Science ®Google Scholar
• ••Original report on the in vitro antifungalactivity of caspofungin.
   Google Scholar
• VAZQUEZ JA, LYNCH M, BOIKOV D, SOBEL JD: In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob. Agents Chemother. (1997) 41:1612–1614.
   PubMed Web of Science ®Google Scholar
• ESPINEL-INGROFF A: Comparison of in vitro activities of the new triazole 5CH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. I Clin. 11/licrobial (1998) 36:2950–2956.
   Google Scholar
• •Study on the in vitro activity of caspofungin against a broad variety of fungal organisms.
   Google Scholar
• MARCO F, PFALLER MA, MESSER SA, JONES RN: Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn. Microbial Infect. Dis. (1998) 32:33–37.
   PubMed Web of Science ®Google Scholar
• •Study on the in vitro activity of caspofungin against clinical bloodstream isolates of Candida spp.
   Google Scholar
• SCOTT PM, GERCKENS L, LYNCH Let al.: Comparative in vitro susceptibility of clinical trial isolates to the echinocandin antifungal MK-991. (1998) 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (1997):J–5.
   Google Scholar
• PFALLER MA, MESSER SA, GEE S et al.: In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. Clin. Microbial. (1999) 37:870–872.
   PubMed Web of Science ®Google Scholar
• SCOTT-HICKS P, DORSO KL, GERCKENS LS et al.: Comparative in vitro susceptibility of clinical trial isolates to the echinocandin antifungal caspofungin (CancidasTM, MK-0991). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (2000):193.
   Google Scholar
• BARCHIESI F, SCHIMIZZI AM, FOTHERGILL AW, SCALISE G, RINALDI MG: In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur. j art Microbial Infect. Dis. (1999) 18:302–304.
   PubMed Web of Science ®Google Scholar
• BACHMANN SP, PEREA S, KIRCKPATRICK WR, PATTERSON TF, LOPEZ-RIBOT JL: In vitro activity of Cancidas (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole-resistance. 40th Interscience Conference 017 Antimicrobial Agents and Chemotherapy (2000):195.
   Google Scholar
• KRISHNARAO TV, GALGIANI JN: Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptocaccus neaformans. Antimicrob. Agents Chemother. (1997) 41:1957–1960
   PubMed Web of Science ®Google Scholar
• NELSON PW, LOZANO-CHIU M, REX JH: In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: influence of assay conditions. I Med. Vet. Mycal (1997) 35:285–287.
   PubMedGoogle Scholar
• •In vitro study demonstrating lack of cross-resistance to existing agents against Candida spp.
   Google Scholar
• CHIN NX, WEITZMAN I, DELLA LATTA P: A study of in vitro antifungal activity of L-743,872 against Fusarium, Rhizopus and Trichosporan species. 36th Interscience Conference 017 Antimicrobial Agents and Chemotherapy (1996):F–37.
   Google Scholar
• DEL POETA M, SCHELL WA, PERFECT JR: In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob. Agents Chemother. (1997) 41:1835–1836.
   PubMed Web of Science ®Google Scholar
• •In vitro study investigating the activity of caspofungin against filamentous fungi.
   Google Scholar
• PFALLER MA, MARCO F, MESSER SA, JONES RN: In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn. 11/licrobial Infect. Dis. (1998) 30:251–255.
   PubMed Web of Science ®Google Scholar
• •In vitro study investigating the activity of caspofungin against filamentous fungi.
   Google Scholar
• FLATTERY AM, HICKS PS, WILCOX A, ROSEN H: In vitro susceptibility of clinical trial isolates of Aspergillus spp. to the echinocandin antifungal caspofungin (CancidasTM, MK-0991). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (2000):938.
   Google Scholar
• ARIKAN S, LOZANO-CHIU M, PAETZNICK V, REX JH: In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob. Agents Chemother. (2001) 45:327–330.
   PubMed Web of Science ®Google Scholar
• STEELE-MOORE, L, MUEHLBAUER L, REINHARDT JF, HOLLOWAY WJ: In vitro comparison of amphotericin B and caspofungin against clinical isolates of Saccharomyces cerevisiae and Aspergillus terreus. Focus on Fungal Infections 11 (2001):23.
   Google Scholar
• KURTZ MB, HEATH IB, MARRINAN J, DREIKORN S, ONISHI J, DOUGLAS C: Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob. Agents Chemother (1994) 38:1480–1489.
   PubMed Web of Science ®Google Scholar
• ••In vitro study examining the effects ofcurrent echinocandins on A. fumigatus.
   Google Scholar
• OAKLEY KL, MOORE CB, DENNING DW: In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob. Agents Chemother. (1998) 42:2726–2730.
   PubMed Web of Science ®Google Scholar
• DOUGLAS CM, BOWMAN JC, ABRUZZO GK et al.: The glucan synthesis inhibitor caspofungin acetate (CancidasTM) kills Aspergillus fumigatus hyphal tips in vitro and is efficacious against disseminated aspergillosis in cyclophosphamide-induced immune suppressed mice. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (2000):387.
   Google Scholar
• ••In vitro study examining the effects ofcurrent echinocandins on A. fumigatus.
   Google Scholar
• RENNIE R, SAND C, SHERBURNE R: Electron microscopic evidence of the effect of LY303366 on Aspergillus fumigatus. 13th
   Google Scholar
• ••Meeting of the International Socieg, for Human and Animal Mycology (1997):P451.
   Google Scholar
• GONZALEZ G, TIJERINA R, NAJVAR L, BOCANEGRA R, RINALDI M, GRAYBILL JR: Correlation between antifungal susceptibilities of Coccidiaides immitis in vitro and antifungal treatment in a mouse model. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (2000):1671.
   Google Scholar
• •Study demonstrating efficacy of caspofungin against experimental coccidioidomycosis and weak in vitro/in vivo correlation.
   Google Scholar
• KOHLER S, WHEAT LJ, CONNOLLY P et al.: Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob. Agents Chemother. (2000) 44:1850–1854.
   PubMed Web of Science ®Google Scholar
• •Study showing moderate efficacy of caspofungin against experimental pulmonary histoplasmosis.
   Google Scholar
• ERNST EJ, KLEPSER ME, ERNST ME, MESSER SA, PFALLER MA: In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn. Microbial Infect. Dis. (1999) 33:75–80.
   PubMed Web of Science ®Google Scholar
• ••Study on the in vitro pharmacodynamicsof caspofungin against Candida species demonstrating fungicidal activity against 4/6 isolates.
   Google Scholar
• KLEPSER ME, ERNST EJ, ERNST ME, PFALLER MA: Growth medium effect on the antifungal activity of LY 303366. Diagn. Microbial Infect. Dis. (1997) 29:227–231.
   PubMed Web of Science ®Google Scholar
• ERNST EJ, KLEPSER ME, PFALLER MA: Post-antifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptocaccus neoformans. Antimicrob. Agents Chemother. (2000) 44:1108–1111.
   PubMed Web of Science ®Google Scholar
• ••Study demonstrating prolonged post-antifungal effects of caspofungin against Candida albicans.
   Google Scholar
• PACKAGE CIRCULAR: Cancidas® (caspofungin acetate for injection). January (2001).
   Google Scholar
• FRANZOT SP, CASADEVALL A: Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptocaccus neoformans in vitro. Antimicrob. Agents Chemother. (1997) 41:331-336. Study demonstrating synergy of caspofungin with amphotericin B against Cr. neoformans in vitro.
   Google Scholar
• MANAVATHU EK, KRISHNAN S, CUTRIGHT JL, CHANDRESAKAR PH: A comparative study of the in vitro susceptibility of Aspergillus fumigatus to antifungal agents individually and in combination by the fractional inhibitory concnetration index, tetrazolium reduction, and radiometric assay. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (2000):931.
   Google Scholar
• ARIKAN S, LOZANO-CHIOU M, PAETZNICK V, REX JH: In vitro synergy studies with caspofungin and amphotericin B against Aspergillus and Fusarium species. 40th Interscience Conference On Antimicrobial Agents and Chemotherapy (2000):932.
   Google Scholar
• •Study demonstrating in vitro synergy or additivity of caspofungin with amphotericin B against the majority of examined Aspergillus and Fusarium spp.
   Google Scholar
• DEL POETA M, CRUZ MC, CARDENAS ME, PERFECT JR, HEITMAN J: Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/ caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptocaccus neoformans. Antimicrob. Agents Chemother. (2000) 44:739–746.
   PubMed Web of Science ®Google Scholar
• CHILLER T, FARROKHSHAD K, BRUMMER E, STEVENS DA: Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus. Antimicrob. Agents Chemother. (2000) 44:3302–3305.
   PubMed Web of Science ®Google Scholar
• •In vitro study suggesting enhanced activity of caspofungin against A. fumigatus in the presence of serum.
   Google Scholar
• CHILLER T, FARROKHSHAD K, BRUMMER E, STEVENS DA: The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus. Diagn. Microbial Infect. Dis. (2001)39:99–103.
   Google Scholar
• •In vitro study suggesting collaboration of caspofungin with mononuclear phagocytes against A. fumigatus
   Google Scholar
• HAJDU R, THOMPSON R, SUNDELOF JG et al.: Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob. Agents Chemother. (1997) 41:2339–2344.
   PubMed Web of Science ®Google Scholar
• ••Original report on the preclinicalpharmacokinetics of caspofungin.
   Google Scholar
• GROLL AH, GULLICK BM, PETRAITIENE R et al.: Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits. Antimicrob. Agents Chemother. (2001) 45:596–600.
   PubMed Web of Science ®Google Scholar
• SMITH JG, ABRUZZO CJ, FLATTERY AM et al.: Evaluation of Pneumocandin L-743872 in neutropenic mouse models of disseminated candidiasis and aspergillosis.
   Google Scholar
• th Interscience Conference on Antimicrobial Agents and Chemotherapy (1996):F–41 Study demonstrating activity of caspofungin against experimental disseminated candidiasis and disseminated aspergillosis.
   Google Scholar
• GRAYBILL JR, NAJVAR LK, LUTHER ME FOTHERGILL AW: Treatment of murine disseminated candidiasis with L-743,872. Antimicrob. Agents Chemother. (1997) 41:1775–1777.
   PubMed Web of Science ®Google Scholar
• ABRUZZO GK, FLATTERY AM, GILL CJ et al.: Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob. Agents Chemother. (1997) 41:2333–2338.
   PubMed Web of Science ®Google Scholar
• ••Original report on the efficacy ofcaspofungin against experimental disseminated candidiasis and aspergillosis and lack of efficacy against disseminated cryptococcosis.
   Google Scholar
• BARTIZAL K, SMITH JG, GILL CJ et al.: Preclinical efficacy of MK-0991 in pancytopenic mouse models of disseminated candidiasis and aspergillosis.
   Google Scholar
• th Interscience Conference on Antimicrobial Agents and Chemotherapy (1997):F–80.
   Google Scholar
• ABRUZZO GK, GILL CJ, FLATTERY AM et al.: Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob. Agents Chemother. (2000) 44:2310–2318.
   PubMed Web of Science ®Google Scholar
• ••Original report on the efficacy ofcaspofungin against experimental disseminated candidiasis and aspergillosis in transiently and chronically leukopenic animals.
   Google Scholar
• GRAYBILL JR, BOCANEGRA R, LUTHER M, FOTHERGILL A, RINALDI MJ: Treatment of murine Candida krusei or Candida glabrata infection with L-743,872. Antimicrob. Agents Chemother. (1997) 41:1937–1939.
   PubMed Web of Science ®Google Scholar
• •Study demonstrating lack of cross-resistance of caspofungin to fluconazole in models of fluconazole-resistant disseminated candidiasis.
   Google Scholar
• FLATTERY AM, ABRUZZO GK, SMITH JG et al.: Activity of pneumocandin L-743872 in a CD4+ T-cell deficient mouse model of oropharyngeal and gastrointestinal candidisis. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (1996):F–40.
   Google Scholar
• ••Original report on the efficacy ofcaspofungin against experimental superficial candidiasis in T-cell deficient animals.
   Google Scholar
• BERNARD EM, ISHIMARU T, ARMSTRONG D: Low doses of the pneumocandin, L-743,872, are effective for prevention and treatment in an animal model of pulminary aspergillosis. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (1996):F–39.
   Google Scholar
• •Study demonstrating efficacy of caspofungin against experimental pulmonary aspergillosis.
   Google Scholar
• GRAYBILL JR, NAJVAR LK, MONTALBO EM, BARCHIESI FJ, LUTHER ME RINALDI MG: Treatment of histoplasmosis with MK-991 (L-743,872). Antimicrob. Agents Chemother. (1998) 42:151–153.
   PubMed Web of Science ®Google Scholar
• POWLES MA, LIBERATOR P, ANDERSON J et al.: Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Prreumocystis carinli. Antimicrob. Agents Chemother. (1998) 42:1985–1989.
   PubMed Web of Science ®Google Scholar
• ••Original report demonstrating efficacyagainst P cariniipneumonitis in experimental models of the disease.
   Google Scholar
• POWLES MA, MCFADDEN DC, LIBERATOR PA et al.: Aerosolized L-693,989 for Prreumocystis canniiprophylaxis in rats. Antimicrob. Agents Chemother (1994) 38:1397–1404.
   PubMed Web of Science ®Google Scholar
• STONE JA, HOLLAND SD, JU WD et al.: Single- and multiple-dose pharmacokinetics of the antifungal agent MK-0991 in man. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (1998): C–51.
   Google Scholar
• •Original report on the plasma pharmacokinetics of caspofungin in human volunteers.
   Google Scholar
• STONE JA, MCCREA J, WICKERSHAM P et al.: A Phase I study of caspofungin evaluating the potential for drug interactions with itraconazole, the effect of gender and the use of a loading dose. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (2000)854.
   Google Scholar
• BALANI SK, XU X, ARISON BH et al.: Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab. Dispos. (2000) 28:1274–1278.
   PubMed Web of Science ®Google Scholar
• ••Original report on the metabolism ofcaspofungin in humans.
   Google Scholar
• XU, DELUNA F, NISHIME J et al.: Lack of metabolism-based drug interactions of MK-0991, a potent antifungal agent, in rats. Pharm. Res. (1997) 14\(Suppl. 11):5558
   Google Scholar
• STONE JA, BALLOW CH, HOLLAND S eta].: Single dose caspofungin pharmacokinetics in healthy elderly subjects. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (2000):853.
   Google Scholar
• SABLE CA, VILLANUEVA A, ARATHON E et al:A randomized, double-blind, multicenter trial of MK-991 (L-743,872) vs. amphotericin B (AMB) in the treatment of Candida esophagitis in adults. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (1997)1B–33.
   Google Scholar
• ••Pivotal Phase II clinical trialdemonstrating safety and efficacy of caspofungin against oesophageal candidiasis.
   Google Scholar
• MAERTENS J, RAAD I, SABLE CA etal.: Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin B, amphotericin B lipid formulations, or azoles. 40th International Conference on Antimicrobial Agents and Chemotherapy (2000):1103.
   Google Scholar
• ••Pivotal Phase II clinical trialdemonstrating safety and efficacy of caspofungin in patients with definite or probable invasive aspergillosis, intolerant of or refractory to standard therapies.
   Google Scholar
• HIEMENZ J, RAAD I, BOOGAERTS M et al.: Efficacy of caspofungin as salvage therapy in invasive aspergillosis compared to standard therapy in a historical cohort. Focus on Fungal Infections 11 (2000:022.
   Google Scholar
• SABLE CA, NGUYEN BY, CHODAKEWITZ JA, DESTEFANO M, BERMAN RS, DINUBILE MJ: Safety of caspofungin acetate in the treatment of fungal infections. Focus on Fungal Infections 11 (2000:021.
   Google Scholar
• ••Summary of safety data from clinical trialswith caspofungin.
   Google Scholar
• GARRISON JC: Histamine, bradykinine, 5-hydroxytryptamine, and their antagonists. In: Goodman and Gilman 's The Pharmacological Basis of Therapeutics. Gilman AG, Rall TW, NiesAS, Taylo P (Eds.), Pergamin Press, New York (1990):574–599.
   Google Scholar